Alnylam Pharmaceuticals announced this week that it has forged an exclusive collaboration with Vancouver, Canada-based Precision Nanosystems to discover and develop novel small lipid nanoparticles using microfluidics, marking the latest in a series of delivery-focused collaborations inked over the past year.

According to the companies, Precision NanoSystems' LNPs are roughly 20 nanometers in size, opening the door to effective siRNA delivery to organs and tissues beyond the liver. Additional terms of the arrangement were undisclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.